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Clinical Material
Ten patients were treated with pempidine, and the trial
extended over a period of about 6 months, but only half of
the patients reached the stage of receiving maintenance treat-
ment with pempidine. These patients all had serious hyper-
tension with secondary cardiovascular and retinal changes
due to the hypertensive state. Patients were first seen and
assessed at the hyperteD5ion clinic, and then admitted for
further investigations and treatment. Investigations were
as thorough and detailed as possible in order to exclude
any aetiological condition which might be curable. L. none
of the 10 cases did we find such an underlying cause.
Of the 10 patients, 5 had malignant hypertension with
papilloedema, of which 3 were cases of essential hyper-
tension, I chronic nephritis, and I a unilateral pyelonephritic
kidney. ~ephrectomy was performed in the last-mentioned
case in an attempt to cure the hypertension, but the hyper-
tension persisted after the operation and a grade-4 retinopathy
remained unchanged. The other 5 patients had severe essential
hypertension.
There were 6 females and 4 males in the series; 6 were in
the relatively young age-group of 30-45 years, while the
patient with chronic nephritis and malignant hypertension
was a child of 14 years. This child was the only case with
a raised blood urea (60 mg. %) at the time treatment was
started.
Two patients were in mild hypertensive cardiac failure,
and only 2 had previously been treated for hypertension-
both with mecamylamine, with an unsatisfactory result.
They also compared pempidine with mecamylamine. Their
findings can be summarized as follows:
1. Like mecamylamine, pempidine is completely absorbed from
the gastro-intestinal tract.
2. Both drugs are excreted by the kidneys, and elimination is
delayed if there is renal failure.
3. The excretion of both mecamylamine and pempidine is
influenced by variation of urinary pH, excretion being reduced by
alkalization of the urine, and increased by acidification. However,
urinary pH changes affect the excretion of pempidine to a lesser
extent than mecamylamine, and pempidine is excreted more
rapidly than mecamylamine no matter whether the urine is acid,
alkaline or normal.
4. The distribution of both drugs in blood and tissues is much
the same, but there is less tissue affinity for pempidine and, unlike
mecamylamine, it is not significantly bound to plasma protein.
This partly explains the more rapid excretion of pempidine, since
a greater fraction of any given dose remains within the extra-
ceUular space, and is therefore available for excretion.
5. The minimum lethal dose of pempidine is considerably
higher than that of mecamylamine.
6. Both drugs readily cross the blood-brain barrier, and are
found in relatively high concentrations in the central nervous
system. The pharmacological effects of lethal doses of pempidine
in rats are similar to those described for mecamylamine," and
include tremor and convulsions.
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Ganglion-blocking agents are undoubtedly the most potent
hypotensive drugs at present available, and extensive research
is being directed to the 9iscovery of similar compounds
which would be safe if given orally and would have less
side-effects. At the moment, however, it is difficult to imagine
that any drug whose main action is blockage of all impulses
at autonomic ganglia can fail to produce unwanted para-
sympathetic effects. Pempidine is the most recently introduced
of these compounds, and so far only one account of its use in
hypertension has been published, by Harrington, Kincaid-
Smith and Milne, l who suggested that pempidine might hold
certain advantages over mecamylamine in the treatment of
.hypertension. Mecamylamine, a secondary amine, has been
more extensively used lately than the quaternary amine
derivatives such as hexamethonium, pentolinium and chlori-
sondamine, mainly because mecarnylamine, in being rapidly
and completely absorbed from the gut,' made oral therapy
more effective and predictable. However, mecamylamine
also has certain disadvantages. Since its excretion is slow
and irregular,' toxic effects from overdosage may be prolonged
for days--even with danger to life.
Paralytic ileus is the most important and serious of these
side-effects. Resultant vomiting and diarrhoea may cause a
reduction of renal blood-flow with further delay in excretion
of the drug, and prolongation of the toxic effects. Patients
with mecamylamine ileus have, on occasion, been diagnosed
by unsuspecting surgeons as cases of acute intestinal ob-
struction, and exposed to the danger of unnecessary laparo-
tomy.a
In view of these disadvantages, a safer and more effective
ganglion-blocking agent has been searched for. We ·were
consequently glad to be able to study the new drug pempi-
dine.t Experimental studies on anirnals4 have shown that
pempidine acts on the autonomic ganglia and that the drug
was more active and less toxic than mecamylamine.
Chemistry and Pharmacology ofPempidine
Pempidine is a tertiary amine and a simple derivative of
piperidine. Pempidine is I : 2 : 2 : 6 pentamethylpiperidine,
and is available for oral use as the bitartrate salt; but the
hydrochloride is preferred for intravenous use. The drug was
originally designated M. & B. 4486, but it is now commonly
known as pempidine (Perolysen May and Baker, or Tenormal
I.CI.).
No detailed pharmacological studies were undertaken in
the present series of patients treated with pempidine. Such
studies were made by Harrington et aP on 32 hypertensives
without renal failure and 2 hypertensives with renal failure.
* Paper presented at the First Scientific Congress of the Associa-
tion of Physicians of South Africa (M.A.S.A.), Cape Town,
January 1959.
t Supplies kindly made available by Imperial Chemical In-
dustries S.A. (pharmaceuticals) Ltd.
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CL!J',T[CAL TRIAL OF PEMPIDINE
During the initial period in hospital, while investigations
were proceeding, all the patients were either sitting up in
bed or in a chair alongside the bed, but no other activity
was allowed at this stage. To allow for uniformity in the
assessment of the.drug, salt restriction was not enforced and
a normal ward diet was allowed.
Once drug treatment had been started, the patient was
encouraged to be up most of the day, and many helped the
nurses in some of their minor ward duties. At night they
slept in a semi-upright position. These measures allowed for
the maximum benefit to be derived from the postural hypo-
tensive effect commOll to all ganglion-blocking drugs. 5
Oral Dosage
Single oral doses of 15 mg. of pempidine bitartrate (7' 5
mg. of pempidine base) were given to 5 patients. A similar
oral dose of mecamylamine was given to the other 5 hyper-
tensive patients in order to compare the onset duration of
action of the two drugs (Fig. 1).
Mter an oral dose of pempidine a hypotensive effect was
usually observed within 1 hour, although in one patient the
onset of action was delayed for 3 hours. The total duration
of hypotensive action was 6-8 hours. The maximal effect
was observed 3-5 hours after the dose, and at this stage most
patients developed postural giddiness on standing up from
a semi-recumbent position. The additional fall of blood
pressure demonstrates the well-known postural hypotension
which occurs after the administration of a ganglion-blocking
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Fig. 2. Increase in- therapeutic action and side-effects of
pempidine when urine was made alkaline. .The curve now
resembles the onset and duration curve of mecamylarnine.
The dotted-line curve shows response to pempidine in the















Comparing these two ganglion-blocking drugs, it can be
seen that similar doses produced a similar hypotensive effect,
but that the onset and duration of action is different. Pempi-
dine acts within 1 hour but action only lasts for 6 hours,
whereas mecamylamine acts within 2 hours and remains
effective for 12 hours. Thus pempidine should be administered
4 times a day, while mecamylamine is usually administered
twice a day, though sometimes a smaller or equal midday
dose is necessary for optimum control of blood pressure.
With both drugs the resulting fall in blood pressure after
a single oral dose was smooth and no undue fluctuation in
pressure occurred. .
Mter a single oral dose of 15 mg. one of the pempidine
patients developed a severe reaction 6 hours after adminis-
tration, viz. an acute gastro-iritestinal upset with vomiting
and diarrhoea, and a few hours later was noted to have some
abdominal distension. Such an incident did not occur with
any of the mecamylamine patients receiving a single large
oral dose. This might suggest that pempidine is the more
toxic of the two drugs when both drugs are employed at the
same dosage.
Effect 0/Alteration in Urinary pH on Excretion 0/Pempidine
It has already been mentioned that Harrington et aP.
showed that the renal clearance of both mecamylamine and
pem,pidine is dependant upon urinary pH, the clearance
being increased in an acid urine and decreased in an alkaline
urine. Variation in excretion, however, was found to be
less with pempidine, and it was stated that the hypotensive
effect was therefore less likely to be influenced by changes
in acid-base balance than with mecamylamine.1
A patient was first given 15 mg. of pempidine orally and
showed the expected response as regards the onset and
duration of action of pempidine. The patient was then given
12 g. of sodium bicarbonate daily for 2 days,. which caused
the urine to become alkaline. Another dose of pempidine
was then given orally', and showed that a significant increase
in the therapeutic action and side-effects of pempidine
occurs when the urine is made alkaline. The duration of
action was now in the vicinity of 14 hours, and postural
hypotension, vomiting and diarrhoea ocx;urred 10 hours
after administration. The curve (Fig. 2fclosely resembles
1
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Fig. 1. Comparison of mecamylamine and pempidine given in
similar oral doses in respect of onset and duration of action.
Arrows indicate duration of postural hypotension and the
additional fall of blo~d .pressure on standing is also shown.
drug. The action of pempidine appears to be indistinguishable
in this respect from that of mecamylamine and lhe other
methonium compounds used in the treatment of hypertension.
The relationship between the extent of the fall of blood
pressure in the horizontal posture and the additional fall of
blood pressure which occurs on standing varies from patient
to patient. Some patients have a substantial fall of blood
pressure in all postures with comparatively little postural
hypotension. Others have very little fall in pressure when
lying flat, but a considerable decrease in blood pressure on
assumption of the erect posture.
After an oral dose of mecamylamine. a hypotensive effect
was observed after about 2 hours. The total duration of
hypotensive action was about 12 hours with the dosage used,
although the maximal effect only lasted for 4-8 hours.
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the onset-duration curve of mecamylamine, which agrees
with the findings of previous workers, l who compared the
cumulative excretion of pempidine and mecamylamine over
24 hours, while varying the urinary pH. It was found that
the lowest rate of excretion of pempidine in an alkaline
urine was sinrilar to the highest rate of excretion of mecamyla-
mine in an acid urine.
Acidification of the urine by giving the patient ammonium
chloride did not produce a striking alteration in the pempidine
onset-duration curve. There was, however, a tendency to a
diIninished therapeutic effect from the drug, and this one
would expect to find due to the more rapid excretion in an
acid urine.
Continuous Oral Treatment
Only 10 patients have been observed on continuous
treatment with pempidine. They were an unselected group,
all of whom had serious hypertf'nsion as assessed from
symptoms, blood pressure readings, retinal vessels, chest
X-ray and electrocardiography. Pempidine was given 4
times during the day, the doses being spaced at 5-hourly
intervals from 7 a.m. to 10 p.m. On this regime a sustained
reduction in blood pressure may be obtained throughout
the day. In some cases the last dose at night was doubled
in order to give a prolonged action during the night hours.
In one patient with impaired renal function the drug was only
given 3 times a day.
Duration 0/ Treatment
Of the 10 patients in the pempidine series, only 5 were
eventually discharged from hospital on pempidine; and these
were well controlled when they. left. In these patients treat-
ment is being continued up to the present time for a period
varying from 8 weeks to 20 weeks. Of the remaining 5, one
died 3 days after starting pempidine, and treatment had to
be stopped in the 4 others because of the severity of side-
effects.
Dosage
The dosage of pempidine required to produce an adequate
hypotensive effect varied widely, in our series from 10 mg.
to 60 mg. daily. The average total daily dose given as
maintenance treatment in this series was 40 mg. of the
bitartrate. In Harrington's series1 the corresponding average
total daily dose was 32· 5 mg.
In our series treatment was usually started with a dose of
2· 5 mg. 4 times a day, and raised rapidly by increasing each
dose by 2· 5 mg. daily until a satisfactory reduction in blood
pressure was achieved or the development of toxic effects
hampered further progress. Once serious toxic effects
occurred, the drug was stopped until the serious symptoms
ceased, and then the administration was resumed at a dosage
reduced to that previously found to be safe. On this safe
dosage, increments were now made-with 2· 5 mg. of pempidine
per day. In this way we were able to control at least 3 patients
who would have been failures in the trial if the recommended
dosage increment of 2· 5 mg. per dose had been adhered to.1
From this experience it appears that the therapeutic and
toxic doses of pempidine lie close to each other. We have
for instance, found on a few occasions that a dose of say
40 mg. daily produced adequate control of blood pressure,
but with 'severe and limiting side-effects; when the dose
was reduced to 37· 5 mg. daily, the drug was tolerable yet
still therapeutically effective. It is possible that had we
tried this dosage scheme earlier on, we might have had
more success with pempidine.
Harrington et af.! did not mention this difficulty in their
trial of pempidine. They increased each dose with 2·5
mg. daily until a satisfactory reduction in blood pressure
was achieved, and found it possible to reach a stable thera-
peutic dose level with reasonable safety within a few days.
ToleranCE
No evidence has been seen of the development of tolerance
to pempidine, analogous t9 that seen with hexamethonium
and other quaternary ammonium compounds.6 In this
respect the drug resembles mecamylamine.
Combination with Other Drugs
In 2 cases reserpine, and in 1 case chlorothiazide, was
added to the pempidine. This was done to try and reduce the
side-effects of pempidine, and in all 3 cases the combination
allowed more successful treatment, suggesting that these
compounds potentiate the action of pempidine as has been
described with other hypotensive agents. 5
Side-effects.
Side-effects (Table I) occurred with disappointing frequency.
Only one of the 10 patients treated with pempidine did not
experience troublesome side-effects. and this patient was
fortunate enough to have her blood pressure controlled on
a very low dosage. viz. 10 mg. per day. Pempidine had to be
abandoned in 5 cases because of the severity of side-effects.
TABLE I. SIDE-EFFECTS OF PEMPIDTh'E (10 PATIENTS)
Alimentary
Dry mouth .. 8
Bitter taste .. 2
Nausea and vomiting 7
Constipation 8
Distention 7
Severe ileus .. 2
Diarrhoea 3
Urinary
Difficulty in micturition 2
Retention 1
Visual
Blurring of vision 3
eNS
Tremors 2
One of these patients subsequently died. but those remaining
have all been successfully controlled with mecamylamine.
Of the 5 patients successfully controlled with pempidine, 3
required laxatives regularly to avoid constipation and, of
these 3, one also required pilocarpine eye drops for blurred
vision, and another neostigmine to relieve the feeling of
fullness and distension which accompanied the constipation.
From the list of side-effects (Table 1) it will be seen that
the most troublesome ones are from the gastro-intestinal
tract, and the severity of these were responsible for cessation
of therapy in one-half of the patients in this small series.
A true ileus with constipation, continuous vomiting and
absence of bowel sounds occurred in 2 patients; this must
be regarded as a very serious complication.
Retention of urine occurred in one patient, a male of 60
years with malignant hypertension, and pempidine had to be
stopped. This patient had previously failed to have his
blood pressure controlled on mecamylamine for the same
reason. He had a transurethral resection for bladder-neck
stenosis, and subsequently we managed to control his blood
pressure reasonably well on pempidine.
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Our pempidine trial came to an abrupt end when one
patient died as a result of a severe ileus, which must be
attributed to the drug.
This patient was an African male aged 60 years with severe
essential hypertension. He presented with headaches and
progressively increasing effort dyspnoea over the previous 2 years.
He also had a chronic cough with mucopurulent sputum, and
suffered from osteo-arthritis. Blood pressure 250/140 mm. Hg.
His heart was enlarged, with a left ventricular type of apex beat,
but he was not in cardiac failure. A grade-2 hypertensive retino-
pathy was found. Routine special investigations did not reveal
anything of note. The blood urea was normal.
Penicillin and streptomycin were given for his mucopurulent
bronchitis, and syrup of codeine phosphate 6-hourly for the
irritating cough. He was started on 2· 5 mg. of pempidine 4 times
a day on 12 November 1958. Ambulation was encouraged. He
was quite well on 13 November, but had no bowel action that day.
His blood pressure, taken 4 times a day, averaged 220/120. Agarol
was prescribed for constipation, and the next morning, 14
November, 2 days after starting pempidine, he complained of
abdominal distension as well as constipation; his abdomen was
found to be distended, but bowel sounds could be heard. The
blood pressure was then 200/120. His urine was strongly acid.
The pempidine was stopped, and the patient was given carbachol,
O' 5 mg. intramusculariy. That same afternoon he started vomiting.
Abdominal distension had increased, and no bowel sounds could
be heard. The blood pressure was now 170/100. The uyinary
output was satisfactory and the urine was still acid.
Intravenous drip and gastric suction were now started, and the
patient was catheterized and continuous bladder drainage instituted.
At first he seemed to improve, but during that night he developed
severe diarrhoea. When seen on 15 November he appeared to be
in a shocked state; pulse 120 p.m., blood pressure 140/100, cold
and sweating. The urinary output was 1 litre and the gastric
suction It litres during the previous 24 hours. The serum electro-
lytes estimated at this stage were normal, except for a rather low
serum-potassium (3·5 mEq. per litre), despite which the electro-
cardiogram, except for a tachycardia, was not significantly different
from that taken on admission.
The patient received It litres of Darrow's solution, 1 litre of
sodium chloride and 2 litres of dextrose water, plus 2 g. of potas-
sium chloride, over the next 24 hours. His condition did not
improve, and finally solucortef was also given intravenously via
the drip.
The blood pressure never fell below 140/100 and urinary
output remained satisfactory throughout this period. The patient
died later that night (I5 November).
At autopsy the pathological diagnosis was paralytic ileus with
meteorism, dilatation and early peritonitis of the small intestine.
Purulent bronchitis and bronchopneumonia were present in both
lungs, the heart showed left ventricular hypertrophy and the
kidneys slight nephrosclerosis. An unexpected finding was the
presence of numerous amoebic ulcers in the caecum, ascending
colon and transverse colon. The patient had never me!:ltioned to
us any complaint referable to this.
As a result of this tragic death it was decided to end the
clinical trial of pempidine, and we have, temporarily at least,
abandoned further use of the drug in the treatment of hyper-
tension. It was interesting to find a recent report' of a patient
who died of severe diarrhoea after mecamylamine treatment.
At necropsy gross ulceration of the colon was present, and
this was thought to be due to a direct local effect of the drug.
In our patient, however, the treatment was not the cause of
the ulcers, for amoebae were seen microscopically.
Results in Cases treated with Pempidine
In 5 patients we obtained a satisfactory control of blood
pressure with pempidine as the major drug used in treatment
(Table II). Parallel with a fall in blood pressure, there
was a general improvement in these patients. Headaches
due to hypertensive treatment disappeared and the patient
with cardiac failure developed a better exercise tolerance
TABLE 11. RESULTS IN 5 PEMPIDn.'E-TREATED CASES
Average BP (mm. Hg) Dose
Retina (mg.per Side-effeCTS
Before After (Keith-Wagener) day)




240/140 160/105 IT4II 20 Constipation
Dry mouth
Bitter taste.
230/130 170/110 II-+II 10
260/150 180/120 IV--7II 60 Severe visual
disturbances.
280/160 180/100 IV--7II 37·5 Dry mouth
Constipation.
and could dispense with the digitalis· and diuretics which
he required before this treatment. Of these 5 patients 3
were cases of malignant hypertension, which was successfully
treated with pempidine. In all 3, 'papilloedema disappeared
after an average treatment period of 6 weeks.
Side-effects were troublesome in 3 of the 5 patients and
they required additional specific treatment for constipation,
dry mouth, blurred vision and a feeling of abdominal disten-
sion.
DISCUSSION
Harrington et al.' also report a syndrome of early paralytic
ileus, with vomiting, abdominal pain and distension in 3
out of 27 patients treated with pempidine. In their cases
the symptoms cleared completely within 12 hours of stopping
the drug. We were less fortunate with this one patient who
died, although our other patient who developed ileus
recovered fairly rapidly, but even here intravenous therapy
and gastric suction were necessary. The only side-effects
Qccuring frequently in Harrington's series of 27 patients,'
were constipation (66%), dryness of the mouth (66%) and
blurring of vision (45 %). The complaints were regarded as
major in only 3 cases.
In our experience· toxic symptoms with pempidine occur
early, usually on the same day as the toxic dose is instituted,
but in 2 cases side-effects were delayed for 2 days. Parallel
with this, a fall of blood pressure has always occurred and
in most cases to a satisfactory level from a therapeutic
point of view. If the same dosage that produced toxicity
originally was given again 1 month later, the same side-
effects occurred, showing that no significant tolerance to
pempidine developed. .
We have also found that there was only a narrow margin
between the toxic and therapeutic doses of pempidine. Patients
fairly comfortably stabilized on a certain dosage, regularly
developed more serious toXic symptoms, such as distension
and vomiting, on a dosage increment of as little as 2·5 mg_
per day.
Comparison with Mecamylamine
Harrihgton et al. 1 concluded from their study of pempidine
that there was little to choose between this drug and mecamy-
lamine in respect of their side-effects. We have, however,
been far less successful with pempidine than with mecamyla-
mine. Our 4 pempidine failures were all controlled and
discharged on mecamylamine. We had the opportunity of
trying only 2 mecamylamine failures on pempidine, and it
was Unsuccessful and had to be abandoned in both.
If we compare our last 20 patients treated on meca-
mylamine, we find that control was easier and there were
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less interruptions caused by stopping and starting the drug.
Consequently the average stay in hospital was shorter.
Side-effects also occurred with mecamylamine, but they
were less frequent and less serious. Constipation and dry
mouth occurred in less than half of our mecamylamine
patients, but in 8 out of 10 of the pempidine series. A true
ileus occurred in 2 of our pempidine patients, but in none
of the 20 mecamylamine-treated group, although it is a
recognized danger with mecamylamine.
SUMMARY AND CO 'CLUSlO 'S
Pempidine has been used as a hypotensive agent in 10 patients
with severe hypertension. Though the series is small, we
have been able to form certain impressions about the drug.
Pempidine given by mouth undoubtedly lowers the blood
pressure in most patients, by virtue of its ganglion-blocking
effect, but it would be wrong to assume that it is an ideal
drug for the treatment of hypertension.
Pempidine has many points of sirr,ilarity to mecamylamine.
Both are freely absorbed from the gut, as a result of which a
constant therapeutic effect from day to day can be obtained
with oral administration. Both are excreted more rapidly
in an acid than in an alkaline urine, and both easily cross
the blood-brain barrier.1
Pharmacologically pempidine has certain advantages over
mecamylamine which should make it a potentially more useful
drug. It is more rapidly excreted, chiefly because of a lower
tissue affinity for the drug, and excretion of pempidine is
less affected by variation in acid balance than that of meca-
mylamine. These pharmacological advantages we have found
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of relatively little account in practice, and severe side-effects,
the main drawback with all ganglion-blocking agents, occur
with disappointing frequency. We have found them to
occur rather more frequently with pempidine than with
mecamylamine, and certainly the gastro-intestinal side-
effects from pempidine seem to be more serious.
After losing one patient from a pempidine ileus, we have
abandoned further use of the drug in the treatment of hyper-
tension. At the moment we do not feel that it can replace
mecamylamine or pentolinium as probably the most useful
drugs for the long-term treatment of severe hypertension.
Pempidine might well be held in reserve. Good control
over blood pressure can be obtained with it in those patients
who are fortunate enough to be able to tolerate it, and
since responses to ganglion-blocking drugs are highly
individual, it is likely that some patients may be more com-
fortable on the one drug than the other, whether this be
mecamylamine, pentolinium, chlorisondamine or pempidine.
I wish to thank: the Medical Superintendent of the Karl Bremer
Hospital, Dr. R. L. M. Kotze, for permission to publish this
report, and ProL A. J. Brink for his stimulating advice and criticism
and for reading the manuscript.
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A PRELIMINARY STATISTICAL SURVEY OF CARCINOMA OF THE OESOPHAGUS
IN THE AFRICAN WITH. SPECIAL REFERENCE TO ACQUIRED
OESOPHAGEAL FISTULAE
JOSEPH KATZ, M.B., F.R.C.S.E., Department of Surgery, and GEORGE. COffiN, M.B., B.CH., D.M.R.D. (R.C.P. & S.),
Department of Radiology, General and Non-European Hospitals, Johannesburg
Fistulae of tlJ.e oesophagus are frequent among the patients
with inoperable oesophageal cancer admitted to the Johan-
nesburg Non-European Hospital over the past 4 years, and
hitherto undescribed peculiarities have been noted.
The oesophagus is an organ peculiarly liable to perfora-
tion. Even in its normal condition, following closely the
course of the lower cervical and thoracic spines, it is com-
paratively friable. Its situation is far posterior and it is
suspended tautly between points of fixation at both upper
and lower ends. This naturally diminishes its mobility.
It is therefore not surprising that, during attempts to over-
come obstruction either instrumental or by natural de-
glutition, an oesophagus which has a further increase in
friability because of disease is not uncommonly subject to
fistula. It is with particular reference to this that we feel
some conclusions can be drawn.
Oesophageal fistulae may be congenital or acquired.
Congenital fistulae have been adequately described in the
literature, but the descriptions of acquired oesophageal
fistulae have been few and inadequate. The following brief
cl.assification of possible causes of acquired fistulae of the
oesophagus may be of help in diagnosis:
I. Neoplaslic. While carcinoma of the oesophagus is the com-
monest cause of oesophageal fistulae,' it is well to remember
that fistulae of the oesophagus sometimes occur as a result
of extra-oesophageal malignancies of trachea, bronchus, larynx,
pyriform fossa,',3 and thyroid.3,.
Il. Inflammatory
(A) Intra-oesophageal
I. ACUTe: Oesophagitis and peptic ulceration.
2. Chronic: (a) Tuberculosis",5" (b) Syphilis.
(B) ExTra-oesophageal
Chronic: (a) Tuberculosis of mediastinal lymph glands and
empyema, .-9 (b) Actinomycosis."l.,ll
Ill. TraumaTic'"
1. Foreign bodies, especially fish and chicken bones."l3
2. Corrosive chemicals-<:austic soda, acids, etc.
3. Indirect crush injuries, e.g. 'stove-in' chest.'
4. Direct injuries, e.g. gunshot' or stab wounds, crush in-
juries,' penetration by fractured bones (ribs, sternum or
vertebrae)?
5. Instruments (a) Dilating bougies, (b) SouUar's tube, (c) Oeso-
phagoscope.l
IV. Spontaneous rupwre, in cases which have been accounted
for by alcohol,'3 severe vomiting," vascular thrombosis and
infarctions of oesophageal wall! cardiospasm; oesophagitis
and peptic ulceration, strictures,' radiation," etc.',·,,,
